New study connects bone drug with combating breast cancer treatment side effects
Oct 10, 2011
Patients who are undergoing treatment in order to combat breast cancer are often faced with troubling side effects that take a toll on their bodies. Now, in breast cancer breakthrough news, an osteoporosis drug may help protect patients' bones from the side effects of breast cancer medications.
According to a new study published in the journal Cancer, aromatase inhibitors have the potential to help stop the growth of certain breast cancer cells. Unfortunately, the drug can cause bone loss and fractures for women.
Now, the researchers are hopeful that the bone drug zoledronic acid could prevent bone loss in postmenopausal women who are also being treated for breast cancer. The study's authors are hopeful that this will help patients lead the highest quality of life possible while undergoing treatment. Zoledronic acid has already been approved by the Food and Drug Administration for treating osteoporosis.
"This study shows that bone loss from aromatase inhibitors can be prevented long term with a safe and effective drug that prevents osteoporosis," said Dr. Adam Brufsky.